10-Q: CV Sciences Reports Mixed Q2 Results Amid Strategic Acquisitions and Cost Reductions

CV Sciences reports a slight decrease in net product sales but improved gross margins in the second quarter of 2024, while also completing two strategic acquisitions.

Summary

• CV Sciences reported net product sales of $3.954 million for the second quarter of 2024, a slight decrease compared to $3.966 million in the same period last year.
• Gross profit for the quarter was $1.860 million, up from $1.718 million in Q2 2023, with a gross margin of 47.0% compared to 43.3% last year.
• The company's total units sold decreased by 12.5% year-over-year, but the average sales price per unit increased by 12.1% due to product and channel mix.
• For the first six months of 2024, net product sales were $7.956 million, down from $8.114 million in the first half of 2023.
• Gross profit for the first six months was $3.713 million, up from $3.500 million in the prior year period, with a gross margin of 46.7% compared to 43.1%.
• The company experienced negative cash flows from operations of $0.6 million for the six months ended June 30, 2024, and had an accumulated deficit of $85.8 million.
• CV Sciences completed the acquisition of Elevated Softgels in May 2024, and Cultured Foods in December 2023, expanding its product offerings and manufacturing capabilities.
• The company is dependent on additional investment capital to fund operations and growth initiatives, and is exploring options to raise funds through capital markets, debt, and lines of credit.
• The company reversed $6.2 million of accrued payroll taxes due to the expiration of the statute of limitations, which significantly impacted the net loss for the period.

Sentiment

Score: 4

Explanation: The document presents mixed results with some positive developments like improved gross margins and strategic acquisitions, but the negative cash flow, accumulated deficit, and dependence on additional capital raise concerns raise significant risks. The legal dispute with the founder also adds uncertainty.

Positives

• Gross profit increased by 8% in the second quarter of 2024 compared to the same period last year.
• Gross margin improved due to product and channel mix, lower inventory losses, and lower freight costs.
• The company successfully acquired Elevated Softgels and Cultured Foods, expanding its product portfolio and market reach.
• The company reduced its cost of goods sold by 7% in the second quarter of 2024 compared to the second quarter of 2023.
• The company's B2C revenue increased by $0.1 million compared to the first six months of 2023, mostly due to additional revenue from subscription customers.

Negatives

• Net product sales remained flat in the second quarter of 2024 compared to the second quarter of 2023.
• The total number of units sold decreased by 12.5% in the second quarter of 2024 compared to the second quarter of 2023.
• The company generated negative cash flows from operations of $0.6 million for the six months ended June 30, 2024.
• The company had an accumulated deficit of $85.8 million as of June 30, 2024.
• The company is dependent on additional investment capital to fund operations and growth initiatives.

Risks

• The company faces intense competition due to a low barrier entry market and a lack of a clear regulatory framework.
• The company is dependent on additional investment capital to fund operations and growth initiatives.
• There is no assurance that the company will be successful in any capital-raising efforts.
• The company's financial operating results and accumulated deficit raise substantial doubt about its ability to continue as a going concern.
• The company is involved in ongoing legal disputes, including a dispute with its founder, which could have a material impact on its financial condition.

Future Outlook

The company anticipates being dependent on additional investment capital to fund operations and growth initiatives and intends to raise funds through capital markets, debt, and lines of credit. The company will continue to work towards increasing revenue and operating cash flows to meet its future liquidity requirements.

Management Comments

• Management implemented, and continues to make and implement, strategic cost reductions, including reductions in employee headcount, vendor spending, and the delaying of certain expenses related to our drug development activities.
• The company intends to continue to innovate new products, build brand awareness, and make significant investments in our business strategy.
• The company intends to make additional acquisitions to further diversify its product offerings.

Industry Context

The CBD market remains fragmented and highly competitive due to a lack of a clear regulatory framework and a patchwork of state regulations. The company is navigating these challenges by focusing on product innovation, brand building, and strategic acquisitions.

Comparison to Industry Standards

• CV Sciences' gross margin of 47.0% in Q2 2024 is a positive sign, indicating improved profitability compared to the previous year. However, it is important to compare this to other companies in the CBD and nutraceutical space to determine if this is a competitive result.
• Companies like Charlotte's Web and Canopy Growth, which are larger players in the CBD market, have faced similar challenges with profitability and regulatory uncertainty. CV Sciences' results should be benchmarked against these companies to assess its relative performance.
• The company's strategic acquisitions of Cultured Foods and Elevated Softgels are similar to moves made by other companies in the industry to diversify product offerings and gain manufacturing capabilities. The success of these acquisitions will be key to CV Sciences' future growth.
• The company's reliance on additional capital raises is a common theme in the industry, as many companies are still in the growth phase and require funding to scale operations. The ability to secure favorable financing terms will be critical for CV Sciences.

Legal Proceedings

• The company is involved in a legal dispute with its founder, Michael Mona Jr., regarding taxes on income received upon the vesting and settlement of RSUs in 2019.
• The company is also involved in a putative class action complaint alleging the labeling on the company's products violated the Food, Drug, and Cosmetic Act of 1938.
• The company is also involved in a shareholder derivative suit alleging breach of fiduciary duty and gross mismanagement.

Related Party Transactions

• The company issued 1,549,410 additional shares of common stock to a vendor as compensation for services provided.
• The company cancelled 11,300,000 fully vested outstanding stock options of Michael Mona Jr. with a weighted average exercise price of $0.42 per share.
• The company reversed $6.2 million of accrued payroll taxes associated with the RSU release to its founder in 2019 due to the expiration of the statute of limitations.

Stakeholder Impact

• Shareholders face uncertainty due to the company's financial challenges and dependence on additional capital.
• Employees may be affected by ongoing cost reductions and potential headcount reductions.
• Customers may benefit from new product launches and expanded offerings due to acquisitions.
• Suppliers may be impacted by changes in the company's operations and procurement strategies.
• Creditors face increased risk due to the company's financial challenges and dependence on additional capital.

Next Steps

• The company intends to continue to build an efficient and cost effective consumer products platform.
• The company intends to continue to evaluate inbound and outbound merger, sale, acquisition or other opportunities.
• The company will continue to pursue actions to increase revenue and operating cash flows to meet future liquidity requirements.
• The company will continue to make and implement strategic cost reductions.

Key Dates

Keywords

CBD, cannabidiol, hemp, supplements, acquisitions, gross margin, financial results, consumer wellness, plant-based protein, softgels